NEO2734 (Synonyms: EP31670) |
Katalog-Nr.GC18750 |
NEO2734 (EP31670) ist ein oral aktiver dualer p300/CBP- und BET-BromodomÄnen-selektiver Inhibitor mit IC50-Werten von <30 nM sowohl fÜr p300/CBP- als auch fÜr BET-BromodomÄnen. NEO2734 ist bei SPOP-Mutanten- und Wildtyp-Prostatakrebs aktiv.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2081072-29-7
Sample solution is provided at 25 µL, 10mM.
NEO2734 (EP31670) is an orally active dual p300/CBP and BET bromodomain selective inhibitor, with IC50 values of <30 nM for both p300/CBP and BET bromodomains[1]. NEO2734 is active in SPOP mutant and wild-type prostate cancer[2].
NEO2734 (1 μM) induces differentiation and G1-phase cell cycle arrest[1].
NEO2734 (1 μM) rapidly induces squamous differentiation in NMC cell lines, and expression of the terminal squamous differentiation marker, involucrin, or keratins[1].
NEO2734 is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo[2].
Reference:
[1]. Chevaun D Morrison-Smit, et al. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Mol Cancer Ther. 2020 Jul;19(7):1406-1414.
[2]. Yuqian Yan, et al. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019 Nov 7;11(11):e10659.
Average Rating: 5
(Based on Reviews and 9 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *